Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LAI · 2 trials · 2 indications
TEAEs are defined as those AEs that occurred on or after the date of first dose of study medication in INS-312 and within 28 days after the last dose. If it couldn't be determined whether the AE is treatment emergent due to a partial onset date, then it was classified as treatment emergent.
Sputum specimens were collected at Screening (Visit 1), Baseline (Visit 2), and at Visits 3 (Month 1) through 8 (Month 6). A negative culture result reflected a negative culture result for all sputum samples collected at each visit. Participants met the primary endpoint of culture conversion by Month 6 if they had 3 consecutive monthly MAC-negative sputum cultures during the first 6 months of the study. A participant needed to achieve the first of 3 consecutive negative sputum cultures (that defined culture conversion) by Month 4 in order to meet the primary endpoint by Month 6. Each participant in the intent to treat (ITT) population (ie, all randomized participants) was classified as either a converter or non-converter by Month 6.
Sputum specimens were collected at screening, baseline (Day 1), during treatment, and at Months 1, 3, 6, and 12 months off treatment. Culture conversion with durability was defined as achieving culture conversion by Month 6 and then having no more than 2 consecutive broth positive cultures and no Agar positive culture up to 3 months off treatment. Converters with missing broth or Agar sputum culture result after Month 6 up to 3 months off treatment were considered as not achieving culture conversion with durability except those participants who are unable to produce sputum despite reasonable efforts, as reported by source documentation. Participants who had relapse/recurrence, had "rescue" medication and/or died before reaching 3 months off treatment were considered as not achieving culture conversion with durability.
| Arm | Type | Description |
|---|---|---|
| Prior LAI + Multidrug Regimen | EXPERIMENTAL | Participants in the prior Study INS-212 who received LAI+MDR. All participants in this safety extension study received LAI+MDR. |
| Prior Multidrug Regimen Alone | EXPERIMENTAL | Participants in the prior Study INS-212 who received MDR alone. All participants in this safety extension study received LAI+MDR. |
| Multi-drug Regimen | NO_INTERVENTION | Participants received their already prescribed anti-mycobacterial regimen (based on the 2007 American Thoracic Society/Infectious Diseases Society of America \[ATS/IDSA\] Guidelines) |
| LAI + Multi-drug Regimen | EXPERIMENTAL | Participants received LAI 590 mg QD in addition to their already prescribed anti-mycobacterial regimen (based on the 2007 ATS/IDSA Guidelines) LAI 590 mg QD, administered by inhaling drug product that had been aerosolized in an eFlow nebulizer over approximately 14 minutes |
| Name | Type | Description |
|---|---|---|
| LAI 590 mg | DRUG | LAI 590 mg QD: administered by inhaling drug product that had been aerosolized in an investigational eFlow nebulizer over approximately 14 minutes |
| Multi-drug regimen | DRUG | Multidrug antimycobacterial regimen from study INS-212 |
| LAI (Liposomal Amikacin for Inhalation) 590 mg | DRUG | LAI 590 mg QD, administered by inhaling drug product that had been aerosolized in an eFlow nebulizer over approximately 14 minutes. |
Key Inclusion Criteria: 1. had successfully completed the Month 6 and End of Treatment visits in Study INS-212 2. had not achieved the INS-212 protocol definition of culture conversion by Month 6 in Study INS-212 OR had experienced a relapse or recurrence by Month 6 in Study INS-212. Key Exclusion...
LAI is an investigational small molecule being developed for the treatment of nontuberculous mycobacterial (NTM) lung infections, including those due to Mycobacterium avium complex (MAC). It is intended for use in combination with a multi-drug regimen for patients with these chronic lung infections.
LAI is being developed by Insmed Incorporated, a biopharmaceutical company traded on NASDAQ under the ticker symbol INSM. Insmed is focused on developing therapies for serious and rare diseases, including nontuberculous mycobacterial lung infections.
LAI is in Phase 3 clinical development. Two Phase 3 trials have been completed: a study evaluating LAI added to a multi-drug regimen compared to the regimen alone, and an open-label safety extension study. LAI remains investigational and is not yet approved by regulatory authorities.
LAI has been studied in two completed Phase 3 trials. NCT02344004 evaluated the efficacy of LAI added to a multi-drug regimen versus the regimen alone in 336 patients with nontuberculous mycobacterial infections. NCT02628600 was an open-label safety extension study in 163 patients with NTM lung infection due to MAC.
The specific molecular target of LAI is not disclosed in the available information. As a small molecule intended for nontuberculous mycobacterial infections, it is designed to be added to a standard multi-drug antibiotic regimen to enhance treatment efficacy, though its precise mechanism of action has not been publicly detailed.